Last update 21 Nov 2024
C-13-60
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms- |
Target |
Mechanism CEA inhibitors(Carcinoembryonic antigen inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
9
Clinical Trials associated with C-13-60Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors
A Safety and Efficacy Clinical Study of CEA-targeted CAR-T Therapy forCEA-positive Advanced/Metastatic Malignant Solid Tumors
嵌合抗原受体T淋巴细胞（C-13-60）制剂治疗CEA阳性晚期恶性实体肿瘤的Ⅰ期临床研究
[Translation] Phase I clinical study of chimeric antigen receptor T lymphocyte (C-13-60) preparations in the treatment of CEA-positive advanced malignant solid tumors
100 Clinical Results associated with C-13-60
Login to view more data
100 Translational Medicine associated with C-13-60
Login to view more data
100 Patents (Medical) associated with C-13-60
Login to view more data
100 Deals associated with C-13-60
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 07 Jun 2022 | |
| Colonic Cancer | Phase 2 | CN | 07 Jun 2022 | |
| Esophageal Carcinoma | Phase 2 | CN | 07 Jun 2022 | |
| Rectal Cancer | Phase 2 | CN | 07 Jun 2022 | |
| Breast Cancer | Phase 2 | CN | 20 Feb 2020 | |
| Lung Cancer | Phase 2 | CN | 20 Feb 2020 | |
| Pancreatic Cancer | Phase 2 | CN | 20 Feb 2020 | |
| Stomach Cancer | Phase 2 | CN | 20 Feb 2020 | |
| Liver Cancer | Discovery | CN | 20 Feb 2020 | |
| Recurrent Carcinoma | Discovery | CN | 20 Feb 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05396300 (ASCO2024) Manual  | Phase 1 | Solid tumor Third line | 40 | (intravenous) | (jgcftkttge) = pxpdpzfkxm xhgdcarmia (tcuytfkupx ) View more | Positive | 24 May 2024 |
(intravenous + Low Dose) | (jgcftkttge) = asfjevmvqt xhgdcarmia (tcuytfkupx ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free